October 21, 2019 / 6:32 AM / 2 months ago

U.S. FDA approves AstraZeneca's diabetes drug for treating heart failure risk

Oct 21 (Reuters) - AstraZeneca Plc said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.

The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval here by the European authorities in August.

Diabetes is associated with a high risk of heart failure. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below